Critical Comparison: XenoPort (XNPT) versus Its Peers

XenoPort (NASDAQ: XNPT) is one of 105 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare XenoPort to related businesses based on the strength of its valuation, analyst recommendations, institutional ownership, earnings, profitability, dividends and risk.

Analyst Ratings

This is a summary of recent ratings and target prices for XenoPort and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XenoPort 0 0 0 0 N/A
XenoPort Competitors 975 3949 6944 186 2.53

As a group, “Pharmaceuticals” companies have a potential upside of 18.47%. Given XenoPort’s rivals higher probable upside, analysts clearly believe XenoPort has less favorable growth aspects than its rivals.

Institutional & Insider Ownership

44.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 11.3% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares XenoPort and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
XenoPort -103.12% -414.36% -37.19%
XenoPort Competitors -2,398.86% -66.10% -7.73%

Valuation and Earnings

This table compares XenoPort and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
XenoPort N/A N/A -5.84
XenoPort Competitors $8.31 billion $1.11 billion 151.96

XenoPort’s rivals have higher revenue and earnings than XenoPort. XenoPort is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

XenoPort rivals beat XenoPort on 7 of the 8 factors compared.

XenoPort Company Profile

XenoPort, Inc. is a biopharmaceutical company. The Company is focused on commercializing HORIZANT (gabapentin enacarbil) Extended-Release Tablets in the United States. The Company’s segment is the development and commercialization of product candidates for the treatment of neurological and other disorders. Its development-stage product candidates include XP23829, XP21279 and arbaclofen placarbil. HORIZANT has been approved by the United States Food and Drug Administration for the treatment of moderate-to-severe primary restless legs syndrome in adults and for the management of postherpetic neuralgia in adults. XP23829 is a fumaric acid ester compound and a prodrug of metabolite monomethyl fumarate being developed for the treatment for patients with moderate-to-severe chronic plaque-type psoriasis and/or patients with relapsing forms of multiple sclerosis. XP21279 is a Transported Prodrug of levodopa being developed for the treatment for patients with idiopathic Parkinson’s disease.

Receive News & Ratings for XenoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XenoPort and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.